In September, Exscientia's short interest dropped by 9.7% to 2,890,000 shares.
Exscientia, an AI-focused pharmaceutical company, experienced a 9.7% drop in short interest in September, totaling 2,890,000 shares. Its short-interest ratio stands at 4.3 days, with 2.7% of shares sold short. The firm is advancing its lead candidate, GTAEXS617, a CDK7 inhibitor in trials. Exscientia has a market cap of $611.69 million and a low debt-to-equity ratio of 0.06, with notable recent investments from firms like Novo Holdings.
October 18, 2024
3 Articles